2026-04-17T19:17:09Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/137122025-10-24T10:43:20Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc Johansson, Erin author ZIMNER RAPUCH, Sarah author Dimitriadis, Georgios K. author Bertrand, Marine author Curteis, Tristan author Ciudin Mihai, Andreea author 2025-09-22T10:49:56Z 2025-09-22T10:49:56Z 2025-09 Type 2 diabetes; Weight management Diabetis tipus 2; Control del pes Diabetes tipo 2; Control de peso Aims This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT-2 and STEP 2. Materials and Methods Participants had body mass index (BMI) ≥ 27 kg/m2, with ≥1 unsuccessful prior dietary weight reduction effort and glycated haemoglobin (HbA1c) 7%–10% on stable therapy. A heterogeneity assessment confirmed that study and patient baseline characteristics were similar. Bucher ITCs compared tirzepatide 10 and 15 mg once-weekly (QW) to semaglutide 2.4 mg QW via placebo, all adjunct to a reduced-calorie diet and increased physical activity. Results Tirzepatide 10 and 15 mg were associated with statistically significant greater reductions in weight, BMI and HbA1c versus semaglutide. Tirzepatide 15 mg was associated with statistically significant greater odds versus semaglutide of ≥5% and ≥15% weight reduction and statistically significant improvements in several cardiometabolic risk factors, including waist circumference, fasting plasma glucose and triglycerides. Both tirzepatide doses showed non-significant trends of greater improvements in high-density lipoprotein, low-density lipoprotein, systolic blood pressure and diastolic blood pressure versus semaglutide as well as a generally comparable safety profile to semaglutide. Conclusions In this ITC versus semaglutide 2.4 mg, tirzepatide 10 and 15 mg were associated with statistically significant greater weight, BMI and HbA1c reduction and tirzepatide 15 mg with statistically significant improvements in multiple cardiometabolic risk factors crucial in managing obesity or overweight among patients with T2D. Both tirzepatide doses also had a generally similar safety profile to semaglutide. Eli Lilly and Company http://hdl.handle.net/11351/13712 Avaluació de resultats (Assistència sanitària) Posologia Obesitat - Tractament Diabetis no-insulinodependent - Tractament ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Obesity Agents Other subheadings::Other subheadings::Other subheadings::/administration & dosage DISEASES::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity DISEASES::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Body Weight::Overweight DISEASES::Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus, Type 2 Other subheadings::Other subheadings::Other subheadings::/drug therapy TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::fármacos antiobesidad Otros calificadores::Otros calificadores::Otros calificadores::/administración & dosificación ENFERMEDADES::enfermedades nutricionales y metabólicas::trastornos nutricionales::hipernutrición::obesidad ENFERMEDADES::afecciones patológicas, signos y síntomas::signos y síntomas::peso corporal::sobrepeso ENFERMEDADES::enfermedades del sistema endocrino::diabetes mellitus::diabetes mellitus tipo II Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes